Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 May 2020)

H. Flick, B. Arns, J. Bolitschek, B. Bucher, K. Cima, E. Gingrich, S. Handzhiev, M. Hochmair, F. Horak, M. Idzko, P. Jaksch, G. Kovacs, R. Kropfmüller, B. Lamprecht, J. Löffler-Ragg, M. Meilinger, H. Olschewski, A. Pfleger, B. Puchner, C. Puelacher, C. Prior, P. Rodríguez, H. Salzer, P. Schenk, O. Schindler, I. Stelzmüller, V. Strenger, H. Täubl, M. Urban, M. Wagner, F. Wimberger, A. Zacharasiewicz, R. Zwick, E. Eber

Wiener klinische Wochenschrift, 2020

The coronavirus disease 2019 (COVID-19) pandemic is currently a challenge worldwide. In Austria, a crisis within the healthcare system has so far been prevented. The treatment of patients with community-acquired pneumonia (CAP), including SARS-CoV‑2 infections, should continue to be based on evidence-based CAP guidelines during the pandemic; however, COVID-19 specific adjustments are useful. The treatment of patients with chronic lung diseases has to be adapted during the pandemic but must still be guaranteed.

Cited by 12 publications.

Field of study: Medicine

10.1007/s00508-020-01691-0